Replies to post #228365 on Biotech Values

[miljenko]

They are not the only one. REGN with Cemiplimab: https://www.clinicaltrials.gov/ct2/show/NCT04046107?term=cemiplimab&draw=2&rank=9
It is NIAID study, still waiting to start. Have no idea for rationale?

[jondoeuk]

The infection drives PD-L1 expression in hepatocytes [1]. Also, HBV-specific T-cells are enriched in the liver, so it makes sense to target the PD-1/PD-L1 axis as this should help restore T-cell function [2].

However, I don't think this will be enough and combinations are needed [3,4].

Refs:
1 https://gut.bmj.com/content/59/Suppl_2/A37.1
2 https://www.gastrojournal.org/article/S0016-5085(09)01747-8/fulltext
3 https://www.gastrojournal.org/article/S0016-5085(12)01292-9/fulltext
4 https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003208